Notably, SB202190 also restored the regulation of MMP2 activity in the 3D hydrogel model, suggesting that p38 MAP kinase inhibitors could be a promising therapeutic strategy for mitigating estrogen-induced collagen degradation in KC. This evidence concerns the gene MAPK14 and keratoconus.